For example, Lee et al. recently published a study in which they assessed the EPR effect in nineteen patients with HER2-positive metastatic BC using a 64Cu-labeled NP (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin) using PET/CT [322]. The gene discussed is ERBB2; the disease is breast cancer.